Clinical examination of a new medical device (MAIA) for conducting visual field tests (microperimetry) compared to the established MAIA-2013 device

Criteria for participation in trial
Inclusion criteria for the group of healthy subjects 1. Age: 18-90 years; 2. Best corrected visual acuity (BCVA): ≥ 0.8 decimal (20/25 ft, +0.1 LogMAR) at least in the study eye; 3. Spherical equivalent between -12 dpt and +6 dpt; astigmatism less than 2 dpt at least in the study eye; 4. Intraocular pressure (IOD) ≤ 21 mmHg in both eyes (Goldmann applanation tonometer); 5. Clinically normal appearance of the optic nerve head (no signs of increased excavation, rim thinning, notches, disc margin hemorrhages, RNFL thinning) in both eyes. This will be examined with Spectralis OCT; 6. Clinically normal appearance of the macula, in both eyes. This will be examined with Spectralis OCT; 7. No ocular pathologies, trauma, surgeries (except for an uncomplicated cataract surgery performed at least 6 months prior to study enrollment) in both eyes; 8. Absence of pathologies that may affect the visual field in both eyes; 9. No intake of medications that may affect the proper execution of perimetry. Inclusion criteria for the group of patients with retinal diseases 1. Age: 18-90 years; 2. BCVA: ≥ 0.1 decimal (20/200 ft, +1.0 logmar) at least in the study eye; 3. Spherical equivalent between -12 dpt and +6 dpt; astigmatism less than 2 dpt at least in the study eye; 4. Diagnosis of any type of retinal disease by the investigator based on funduscopy and Spectralis OCT, for which a microperimetry examination is indicated, at least in the study eye. This includes, among others: early and intermediate age-related macular degeneration (AMD), geographic atrophy (GA), neovascular AMD, history of retinal pigment epithelium (RPE)-choroid transplantation, diabetic retinopathy (DR), retinal vascular diseases, pathological myopia, retinal dystrophies, vitreoretinal interface disorders, inflammatory chorioretinal disorders, toxic retinopathies, glaucoma, and others. (BASEC)

Exclusion criteria
Exclusion criteria for the group of healthy subjects 1. Glaucoma or glaucoma-suspect diagnosis in either eye; 2. Presence or history of ocular hypertension (IOD ≥ 22 mmHg) in either eye; 3. Presence or history of disc margin hemorrhage in either eye; 4. Amblyopia in either eye; 5. Nystagmus or poor fixation in either eye; 6. Previous laser or other eye surgeries, including uncomplicated cataract surgeries, performed within 6 months prior to study enrollment in both eyes; 7. Any active infection of the anterior or posterior segments of the study eye; 8. Subjects with significant media opacities preventing acceptable quality of fundus imaging in the 9th infrared domain (IR) of the study eye; 9. Signs of diabetic retinopathy, diabetic macular edema, or other retinal diseases in either eye; 10. Intake of medications that may affect the proper execution of MP or may lead to visual field losses; 11. Intolerance to ophthalmic imaging; 12. Claustrophobia; 13. Inability to provide informed consent. Exclusion criteria for the group of patients with retinal diseases 1. Any ophthalmic surgery on the study eye. Exception: uncomplicated cataract surgery performed at least 6 months prior to the start of the study; 2. Subjects who cannot tolerate ophthalmic imaging; 3. Nystagmus in either eye; 4. Subjects with significant media opacities preventing acceptable quality of IR fundus images in the study eye; 5. Intake of medications that may affect the proper execution of MP or may lead to visual field losses; 6. Claustrophobia; 7. Inability to provide informed consent; 8. In the investigator's assessment, at-risk subjects (i.e., recent [3 months] or imminent deterioration of vision [3 lines on an ETDRS visual acuity chart]). (BASEC)